Lambert-eaton myasthenic syndrome

被引:0
作者
Maria B. Weimer
Joaquin Wong
机构
[1] Louisiana State University Health Sciences Center,Department of Neurology
来源
Current Treatment Options in Neurology | 2009年 / 11卷
关键词
Plasma Exchange; Main Side Effect; Compound Muscle Action Potential; Pyridostigmine; Neuromuscular Transmission;
D O I
暂无
中图分类号
学科分类号
摘要
Lambert Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disease. Often, the signs and symptoms of LEMS are mistaken for myasthenia gravis and therefore the workup is misdirected. A physician must look for an occult malignancy when the diagnosis is made and then continue to search for a malignancy for at least 5 years after diagnosis. The diagnosis of LEMS can be confirmed with electrophysiologic studies or with serum calcium channel antibodies. In most patients with LEMS, 3,4-diaminopyridine will improve strength. In patients without malignancy, immunosuppressants do have a role in the treatment of LEMS. Patients and physicians must be aware that certain situations and drugs may exacerbate weakness.
引用
收藏
页码:77 / 84
页数:7
相关论文
共 104 条
  • [91] ten Broek-Pastoor J.M.(undefined)undefined undefined undefined undefined-undefined
  • [92] Argov Z.(undefined)undefined undefined undefined undefined-undefined
  • [93] Mastaglia F.L.(undefined)undefined undefined undefined undefined-undefined
  • [94] Smith A.G.(undefined)undefined undefined undefined undefined-undefined
  • [95] Wald J.(undefined)undefined undefined undefined undefined-undefined
  • [96] Bosdure E.(undefined)undefined undefined undefined undefined-undefined
  • [97] Attarian S.(undefined)undefined undefined undefined undefined-undefined
  • [98] Mancini J.(undefined)undefined undefined undefined undefined-undefined
  • [99] Shapira Y.(undefined)undefined undefined undefined undefined-undefined
  • [100] Cividalli G.(undefined)undefined undefined undefined undefined-undefined